Novartis AG (NYSE:NVS)

86.91
Delayed Data
As of Feb 16
 +0.23 / +0.27%
Today’s Change
72.67
Today|||52-Week Range
94.19
+3.51%
Year-to-Date
Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles
Feb 16 / TheStreet.com - Paid Partner Content
Intercept Starts OCA Trial for NASH Patients With Cirrhosis
Feb 13 / Zacks.com - Paid Partner Content
Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion
Feb 16 / Zacks.com - Paid Partner Content
Axovant Shares Crater as CEO and President Both Resign
Feb 12 / TheStreet.com - Paid Partner Content
Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales
Feb 15 / Zacks.com - Paid Partner Content
Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?
Feb 12 / Zacks.com - Paid Partner Content
Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva
Feb 15 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Novartis, BP and Biogen
Feb 09 / Zacks.com - Paid Partner Content
Roche's Rituxan Gets Priority Review for Label Expansion
Feb 14 / Zacks.com - Paid Partner Content
Top Research Reports for Novartis, BP & Biogen
Feb 08 / Zacks.com - Paid Partner Content
Lilly's Taltz Positive in Phase III Label Expansion Study
Feb 14 / Zacks.com - Paid Partner Content
Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis
Feb 08 / Zacks.com - Paid Partner Content
Teva Stock Falls as Novartis Brings Another Copaxone Generic
Feb 14 / Zacks.com - Paid Partner Content
Array's Melanoma Combo Shows Positive Overall Survival Data
Feb 07 / Zacks.com - Paid Partner Content
Generic Drugmakers to Dump as Teva's Woes Continue in 2018
Feb 13 / Zacks.com - Paid Partner Content
Roche Reports Positive Data From Tecentriq-Avastin Study
Feb 06 / Zacks.com - Paid Partner Content
The Quest to Develop the First Alzheimer's Disease Treatment
Feb 13 / GuruFocus News - Paid Partner Content
Trump wants to fix 'injustice' of high drug prices. But can he?
Jan 31 / CNNMoney.com
Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug
Feb 13 / TheStreet.com - Paid Partner Content